Acute Effect of Nitrate From Natural Dietary Sources on Arterial Stiffness and Blood Pressures in Healthy Individuals

NCT ID: NCT01604993

Last Updated: 2014-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the acute effect of a meal high in dietary nitrates on aortic augmentation index, brachial and aortic blood pressures, and subendocardial viability ration (SEVR).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypertension has become a common medical condition worldwide, raising public concern regarding the accompanying increase in cardiovascular disease risk and other health risks. Targets for optimal blood pressure are often unmet by conventional pharmaceutical therapies; consequently, complementary and alternative medicines are increasing in popularity among patients wishing to better manage their BP. In the case of hypertension, endothelial dysfunction and cardiovascular disease, a decline in the ability of blood vessels to dilate in response to shear stress is a major contributor to vascular pathology. At the core of these conditions is a decreased ability to synthesize nitric oxide, a potent vasodilatory agent. The proposed study will examine whether or not increasing the intake of dietary nitrate, which can be converted to nitric oxide endogenously, can improve three indices of vascular function that are validated risk factors for CVD: arterial stiffness, as measured by aortic augmentation index (AIx), aortic BP and brachial BP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High nitrate dietary source

556 grams of high nitrate spinach soup that is orally consumed as a single dose for 7 days.

Group Type EXPERIMENTAL

Spinach soup

Intervention Type OTHER

556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days

No Nitrate dietary source

556g low nitrate asparagus soup; orally consumed as a single does for 7 days.

Group Type PLACEBO_COMPARATOR

Asparagus soup

Intervention Type OTHER

556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spinach soup

556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days

Intervention Type OTHER

Asparagus soup

556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers aged 18-50
* Must consider themselves to be in good overall health and be free of any conditions or illnesses Women must be post-menopausal or not pregnant.
* Body mass index (BMI) must be \<30kg/m\^2.
* Normotensive, as defined by brachial SBP \<140mmHg and DBP \<90mmHg
* Subjects must also be willing to stop using mouthwash for the duration of their participation in the study.

Exclusion Criteria

* Women of childbearing age may not be pregnant, planning to become pregnant, or breastfeeding at the time of the study
* BMI \>30kg/m\^2
* Hypertensive as defined by brachial SBP \>140mmHg and/or DBP \>90mmHg
* Allergy or sensitivity to the study product, reference therapy or nitrates
* Having any gastrointestinal complication or condition
* Chronic use of medications such as prescription NSAIDs, antacids, blood-thinners, hypertensive medications, medications affecting NO synthesis such as Viagra, and use of antibiotics within one month of the study start
* Individuals who are involved in another clinical trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Unity Health Toronto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vladimir Vuksan, PhD

Role: PRINCIPAL_INVESTIGATOR

Risk Factor Modification Centre - St. Michael's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Risk Factor Modification Centre

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11216

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Aspirin Resistance in Coronary Artery Disease
NCT00753935 COMPLETED EARLY_PHASE1
Physicians' Health Study
NCT00000500 COMPLETED PHASE3